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EpilepsyWereport data from two patientswho developed reversible downbeat nystagmus (DBN)while usingAEDswith-
in the therapeutic range. All previous reported cases of epilepsy with drug-induced DBN related to toxic levels of
AEDswere summarized, andDBNwas foundmostly occurring in those using a sodium channel blocking AED.We
propose that in our cases, the DBN with therapeutic AED levels may be explained by additive effects of sodium
channel blockers. Adverse drug effects should be considered as a cause of DBN in people with epilepsy treated
with multiple AEDs.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Iatrogenic down beat nystagmus (DBN) in people with epilepsy is
rare and has been reported in the context of intoxication with antiepi-
leptic drugs (AEDs) [1]. We describe two patients who developed
reversible DBN while using AEDs within the therapeutic range.
2. Case reports
2.1. Case 1
A 30-year-old man with refractory epilepsy following perinatal oc-
cipital lobe infarction was referred to our center with episodes of
oscillopsia 1 h after taking his AEDs (lamotrigine 150 mg bid, valproic
acid 600 mg bid, gabapentin 400 mg tid, and carbamazepine 400 mg
bid). He noted that oscillopsia while reading could be prevented by
keeping his book upward. He had DBN on examination. All AED levels
were within the therapeutic range (Table 1). Downbeat nystagmus dis-
appeared immediately after reduction of lamotrigine; subsequently,
gabapentin was withdrawn without seizure increase.
2.2. Case 2
A 38-year-old womanwith refractory epilepsy due to tuberous scle-
rosis complex and a hypothalamic giant cell astrocytoma presented
with oscillopsia. She had weekly clusters of predominantly complexeiden UniversityMedical Centre
; fax: +31 23 558 8159.
. This is an open access article underpartial seizures despite taking multiple AEDs. The complaints started
following a change of medication: introduction of lacosamide 100 mg
bid and tapering of topiramate. At the time of referral, she used valproic
acid, levetiracetam, lamotrigine, and topiramate (Table 1). The
oscillopsia was continuous without clear ﬂuctuations following drug
intake. Downbeat nystagmus and ataxia were noted at examination.
There was no evidence of AED intoxication (Table 1). Lacosamide was
discontinued, and the DBN and ataxia disappeared.
3. Discussion
In these cases, the drug levels were within the therapeutic range,
but the temporal relationship between oscillopsia and drug ingestion
(Case 1), the response to change to thedrug treatment (Case1 andCase2),
and also the impressive amount of AEDs suggested a drug-related cause.
An ultimate proof would require a drug challenge, but this was not
feasible in these cases.
Downbeat nystagmus is thought to result from impairment of the
vestibulocerebellum, ﬂocculus, or paraﬂocculus, that serves as the out-
put pathway for information on movement, coordination, and balance
from the cerebellar cortex [1–3]. In our two cases, the relevant drugs
lamotrigine and lacosamide are both sodium channel blockers. In addi-
tion, both subjects were on combination therapy with other AEDs with
sodium channel blocking properties (carbamazepine and valproic acid
in Case 1, lamotrigine and valproic acid in Case 2). We reviewed the
PubMed database (search terms: DBN and epilepsy) and identiﬁed
nine previously reported cases with epilepsy and drug-induced DBN
(Table 1).Most caseswere related to toxic AED levels (lamotrigine, phe-
nytoin, and felbamate). In one case, lamotrigine toxicity was likely, but
not established; in another case, DBN was associated with therapeuticthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Summary of previous reported and presented cases with epilepsy and anticonvulsant-induced downbeat nystagmus (DBN).
Age Sex Etiology Speciﬁc cause Medication: total daily dosage (mg) AED serum levels with,without DBN (μg/ml)
Absence of DBN
following AED
reduction (R) or
withdrawal (W)
Reference
23 F Unknown Lorazepam 2
Lamotrigine 400
Gabapentin 1200 Lamotrigine 19.9# Lamotrigine (R) [4]
34 F Structural Meningitis Lamotrigine 500 Valproic acid 1250 Lamotrigine 27.0#,
18.8
Valproic acid (R) [4]
31 F Unknown Carbamazepine 1200
Topiramate 200
Lamotrigine 600 Carbamazepine 9.4 Lamotrigine not
assessed
Lamotrigine (R) [5]
51 M Structural Gunshot Phenytoin 400 Phenytoin 38#, 18 Phenytoin (W) [6]
54 F Unknown Phenytoin 400
Phenobarbital 120
Primidone 250
Perphenazine 12
Thioridazine 200
Phenytoin 27#, 14
Phenobarbital 24
Primidone 6.3 Phenytoin (W) [6]
19 F Unknown Phenytoin 150
Carbamazepine 800
Primidone 750 Phenytoin 14, 14 Primidone 22#, 15 Phenytoin (R) [7]
23 F Structural Adhesions found in
posterior fossa
(Meningitis?)
Primidone 750
Phenytoin 300
Carbamazepine 800
Acetazolamide
1000
Methosuximide
600
Phenytoin 20#, 9.8
Primidone 6
Carbamazepine 3.5
Methsuximide 1.7
Phenytoin (W) [7]
18 F Unknown Carbamazepine 1800 Carbamazepine 9.6,
6.9
Carbamazepine
(R)
[8]
44 M Structural Concussion Felbamate (dosage not
reported)
Haloperidol 3
Benztropine 2
Felbamate 110# Felbamate (W) [9]
30 M Structural Perinatal occipital lobe
infarction
Valproic acid 1200
Carbamazepine 1200
Lamotrigine 300
Gabapentin 3600
Valproic acid 65, 44
Carbamazepine 8.4, 6.8
Lamotrigine 9.08, 6.8
Gabapentin 11.5, 3.8
Lamotrigine (R)
Gabapentin (W)
This paper
38 F Structural Tuberous sclerosis
complex; hypothalamic
giant cell astrocytoma
Valproic acid 2000
Levetiracetam 2000
Lamotrigine 200
Lacosamide 200
Valproic acid 74, 53
Levetiracetam 19.1,
23.2
Lamotrigine 7.6, 7.1
Lacosamide 5.0
Lacosamide (W) This paper
DBN = downbeat nystagmus, AED = antiepileptic drug, F = female, M =male.
# Toxic level.
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fractory epilepsy, and most (7 out of 9) were using multiple AEDs. All
AEDs that have been associated with DBN (carbamazepine, phenytoin,
lacosamide, and lamotrigine) have sodium channel blocking properties
except for felbamate.
Voltage-gated sodium channel (Nav) 1.1 and Nav1.6 channels are
the primary voltage-activated sodium channel isoforms expressed in
cerebellar Purkinje neurons and might explain the association between
DBN and sodium channel blocking AEDs [10]. We suggest that the
occurrence of DBN within the therapeutic range may be explained
by additive effects of sodium channel blockers as in our two cases
or by an increased propensity for DBN due to epilepsy etiology
(e.g., encephalopathy with cerebellar dysfunction).
4. Conclusion
Adverse drug effects should be considered as a cause of DBN in
people with epilepsy treated with multiple AEDs, particularly those
with sodium channel blocking properties even in the absence of toxic
levels. Prompt recognition of this adverse effect is important to avoid
an incorrect diagnosis.
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